Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Quality Of Life Companion Study For JMA27 (NCIC-MA.27): A Randomized Phase III Trial Of Exemestane Versus Anastrozole With Or Without Celecoxib In Postmenopausal Women With Receptor Positive Primary Breast Cancer
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00090974, this observational or N/A phase trial focuses on Breast Cancer and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2023 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jul 2023 [monthly]
Completed
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed
Status: Unknown Status → Completed
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Unknown Status NA
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .